JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
NCT ID: NCT04951947
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
30 participants
INTERVENTIONAL
2023-06-01
2025-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)
NCT03904719
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
NCT05158491
CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
NCT03848611
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer
NCT03971214
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
NCT05001724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Treatment arm
JS201 combine with Lenvatinib
JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JS201 combine with Lenvatinib
JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. The patient failed first-line EC+PD-L1 treatment
* 3 PS 0-1
Exclusion Criteria
* 2\. Women during pregnancy
* 3\. Patients with symptomatic brain metastases
* 4\. PS≥2
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hunan Province Tumor Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yongchang Zhang
Director, Head of Medical Oncology, Principal Investigator, Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yongchang Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Hunan Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hunan Cancer Hospital
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.